McKesson Corporation (MCK) CEO Brian Tyler on Q3 2022 Results – Earnings Call Transcript

McKesson Corporation (NYSE:MCK) Q3 2022 Earnings Conference Call February 2, 2022 4:30 PM ET

Company Participants

Rachel Rodriguez – VP of Investor Relations

Brian Tyler – Chief Executive Officer

Britt Vitalone – Chief Financial Officer

Conference Call Participants

Eric Percher – Nephron Research

Lisa Gill – JPMorgan

Charles Rhyee – Cowen

Jailendra Singh – Credit Suisse

Michael Cherny – Bank of America

Brian Tanquilut – Jefferies

Ricky Goldwasser – Morgan Stanley

Steve Valiquette – Barclays


Good day, ladies and gentlemen and welcome to McKesson’s Third Quarter Fiscal 2022 Earnings Conference Call. Please be advised today’s conference is being recorded. At this time, I’d like to turn the call over to Rachel Rodriguez, VP of Investor Relations. Please go ahead.

Rachel Rodriguez

Thank you, Keith. Good afternoon and welcome everyone to McKesson’s third quarter fiscal 2022 earnings call. Today I’m joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. Brian will lead off followed by Britt, and then we will move to a question-and-answer session. Today’s discussion will include forward-looking statements, such as forecasts about McKesson’s operations and future results.

Please refer to the cautionary statements in today’s earnings release and presentation slides available on our website at and the risk factors section of our periodic SEC filings for additional information concerning risk factors that could cause our actual results to materially differ from those in our forward-looking statements.

Information about non-GAAP financial measures that we will discuss during this webcast, including reconciliation of these measures to GAAP results can be found in today’s earnings release and presentation slides. The presentation slides also include a summary of our results for the quarter and updated guidance assumptions. With that, let me turn it over to Brian.

Brian Tyler

Thank you, Rachel and thank everyone for joining us on our call today. Today we reported third quarter fiscal 2022 results, another quarter with double-digit adjusted operating profit growth in all four segments, reflecting strength in the fundamentals across our businesses. Our focus and execution against our company priorities positions us consistently generate strong financial results despite fluidity we continue to see in the macro economic environment.

Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities we have been sharing with you our strategic transformation to a diversified healthcare services company centered around a set of four enterprise priorities. We believe that execution against these priorities is critical to our ability to generate long-term sustainable growth and we want to reiterate our focus and commitment to each one of them. Our first priority is our people, our teams and our culture.

Through our diversified portfolio of assets and operations, we as a company touch and impact many aspects of health in the healthcare system, including patients embedded in our daily operations is our purpose, advancing health outcomes for all and our mission of building an impact driven organization. We’ve been focused on enabling change in three areas, improving access to healthcare, advancing health equity, and protecting our environment.

In the past year, our employees came together and shared countless moments of impact, finding new ways to get involved and to contribute. In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly 1,500 charities. I couldn’t be more proud of what we’ve achieved so far. And I’m confident in our ability to build a brighter future that in fact, offers greater health outcomes for all. Part of our focus on culture is our continued improvement in diversity and inclusion. We put a particular focus on hiring, developing and promoting what we call a best talent strategy at McKesson.

Recently, we were recognized as one of the best places to work for LGBTQ equality, the ninth year in a row we’ve received this honor. Our commitment to diversity and refreshment includes our board of directors. In January, we welcome James Hinton and Kathleen Wilson-Thompson as new independent directors to our board of directors. Both James and Kathleen have served in multiple senior leadership roles within the healthcare industry.

Currently, Jim serves as an operating partner for the private equity firm Welsh, Carson, Anderson & Stowe and prior to that, he held the role of Chief Executive Officer at Baylor Scott & White Health. And Kathleen, most recently held the role of Executive Vice President and Global Chief Human Resource Officer at Walgreens Boots Alliance, where she led the Human Capital Strategy including merger integration and HR transformation through digitization.

Their decades of healthcare experience and proven record leading complicated organizations and executive leadership roles will be instrumental to McKesson, and we are excited to welcome them to our board. Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our Board, which will go into effect on April 1, following a plan transition led by our current Independent Chair Edward Miller. I want to thank Ed for his years of steady leadership and invaluable contributions as the Independent Chair to McKesson’s board of directors. And I also want to welcome Don to his new role. He brings deep leadership expertise and shares McKesson’s values, culture, strategy, and vision including his commitment to board diversity, we look forward to his leadership and stewardship.

Our next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. We have a vast scale distribution network and deep expertise in global supply chain management, which have been a critical and foundational part of our long history. We’re proud of our operational excellence and our ability to capture efficiency and deliver consistent and high quality service to our customers while optimizing operating margin.

Building off of this core capability, we’ve been very successful and expanding into new product categories and new adjacent markets like our lab solutions and our government partnership strategies. Our scaled assets and capabilities also enable us to play an integral role in the response to the COVID 19 pandemic. We’re proud to serve as a centralized distributor of vaccines and ancillary supplies for the U.S. government. We’ve also been working closely with our partners, suppliers and manufacturers to navigate the complex supply chain system.

These relationships have allowed us to continue to provide stability of supply and low costs for our customers. And as a result, we’ve been able to manage through some of the challenges that the market has been seeing. Our third priority is to streamline the business, which includes initiatives like the split-off of change healthcare and our strategic intent to fully exit the European region. We recently announced the sale of our Austrian business which was completed on January 31 and we have agreements to sell 10 of the 12 countries where we operate.

As a reminder, Norway and Denmark remain the only countries that we have not entered into an agreement to sell. We continue to work towards the closing of the other pending divestitures. These transactions are the result of our intentional effort to evaluate and assess our portfolio for strategic alignment. We believe that by fully exiting the Europe region, we’ll be able to better focus our human and financial capital into higher growth and higher margin areas, which leads me naturally to our next company priority. The last company priority is our strategic growth pillars, oncology and biopharma services. Over the past few years, we set out to accelerate the growth in these two areas, and build out what we refer to as ecosystems.

As we shared in our Investor Day in December, these are both large and growing markets that have significant unmet needs and opportunities and we are tackling some of the most complex problems in the healthcare system with the goal to bring efficiency and benefits to all stakeholders across these ecosystems. In the oncology ecosystem, our growth strategy is centered around our support for the large growing and diversified U.S. oncology network. With the reach of over 1,400 physicians, the U.S. oncology network treats 15% of all new cancer patients in the U.S. at one of its 500 sites of service.

One of the U.S. oncology networks important initiatives is its participation in the oncology care model, which is a five year experimental payment model with the goal of bringing down the cost of cancer. Based on the latest results, the U.S. oncology network practices participating in the program, achieved high marks on quality metrics and provided significant cost savings to Medicare. By representing approximately one-fourth of all providers participating in the program, the U.S. oncology network demonstrated its leadership role in transitioning healthcare to a more value based approach.

Building upon our deep reach in the Community Oncology space, we’re creating an oncology ecosystem with multifaceted service offerings that are all interconnected. At the center of this connectivity is Ontada, oncology, technology and insights business dedicated to help advanced cancer research and advanced patient care. We recently highlighted this business at our Investor Day.

Since its launch in December of 2020, the team has made great progress transforming ideas into reality. Ontada signed two agreements with strategic partners to improve patient outcome and quality of patient care and it was instrumental in the launch of The MYLUNG consortium which through real world research and study provides critical information to improve the patient’s journey. Within our biopharma ecosystem, we build a set of differentiated assets and capabilities, including businesses like RelayHealth Pharmacy, CoverMyMeds and RxCrossroads. They’re combined under the prescription solutions business with a shared goal to improve access, adherence and affordability of medicines.

One of the key customers of our business is biopharma companies, through our scale and interconnected technology network, we provide biopharma a range of commercialization services and by automating and simplifying the process of prior authorization, we reduce prescription abandonment and provide biopharma access to new patients. Our unique technology capabilities also generate insights into patients needs and challenges enabling greater ability to impact patient actions and get better outcomes.

We support over 650 brands today covering 94% of the therapeutic areas and we’re connected to all the major insurance companies and most of the regional payers in the United States. The reach of our network is deep and broad, which is why it’s the foundation of our biopharma ecosystem and we are incredibly excited about the market opportunities it brings. Our progress with each of the company priorities has been truly outstanding and we see the strategies working. The strong conviction in these priorities will be our NorthStar as we seek to advance and win in the marketplaces as a diversified healthcare service company and to drive long-term sustainable growth for our shareholders.

Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a broad resolution of governmental opioid related claims. To date, 46 states, all five U.S. territories and Washington DC have joined the proposed settlement to sign on period for political subdivisions in participating states to join the previously announced Proposed Opioid Settlement Agreement founded on January 26. We have now entered into the evaluation period. The deadline for our decision is February 25 2022. We continue to work with all parties to bring meaningful relief to effective communities and towards resolutions which will allow us to further focus on the strategic priorities of our business.

Now, let me get to the results. We’re pleased to report a strong third quarter with total company revenues of $68.6 billion and an adjusted earnings per diluted share of $6.15 ahead of our expectations. As a result of our performance in the underlying business and the contribution from COVID-19 related items, we’re raising our adjusted earnings per diluted share guidance to $23.55 to $23.95. This is from the previous range of $22.35 to $22.95.

The third quarter was another example of the nonlinear nature of the recovery from the pandemic. At the beginning of the quarter, volume and utilization trends were recovering as COVID 19 cases continue to decline across the country. Although we expected a nonlinear recovery trend, emergence in the spread of the Omicron variant in December was unexpected. Since then, we’ve been closely monitoring its impact. One thing we’ve learned in the past two years is the resilience of our business and our communities. Regardless of the trajectory of the pandemic, we’re confident about our ability to adjust and adapt to support our customers and their patients in these challenging times.

Let’s turn to the U.S. Pharmaceutical segment. U.S. Pharmaceutical segment saw 12% adjusted operating profit growth, which was underpinned by the contribution from COVID-19 vaccine distribution and increased specialty volume. Through the third quarter and into January, branded pharmaceutical pricing is tracked in line with our original expectations, and consistent with our experience over the past several years.

For generics we continue to benefit from the success and strength of our sourcing operation with ClarusONE. We have not only the scale, but the procurement expertise to consistently source products at low cost while protecting the integrity and the safety of the supply chain. We are also proud of our role in supporting the U.S. government’s pandemic response effort as the vaccine and booster recommendations for various age groups continues to expand and evolve. Through January 31, our U.S. pharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID-19 vaccines to International Donation Mission. In January, U.S. government extended the existing COVID-19 vaccine and distribution contract through July of 2022 which is roughly in line with the first quarter of our fiscal 2023.

In prescription technology solutions, the segment had excellent momentum and delivered an 11% increase to segment adjusted operating profit in the third quarter. As I mentioned earlier, we offer a range of commercial services primarily to biopharma companies. And this quarter the growth was led by third-party logistics services and our access adherence and affordability solutions, including our access for more patients product. This segment aligns with our focus on developing the biopharma services ecosystem. The market that we’re focused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 billion with good growth potential and an attractive margin profile.

We are pleased with the financial performance and expect to continue to drive, while growing the business. With surging demand and a complex supply chain our new products playing an important role in the fight against the pandemic. The dedicated team and med surge is the foundation to our business growth, and we continue to invest to ensure operational continuity and excellence.

As it relates to our international segment, we continue to benefit from COVID-19 related programs and our European operations in Canada. Through December, we’ve distributed over 81 million vaccines to administration sites in select markets across our international geographies. As we look forward to fiscal 2023, I’m most excited about the progress on the four company priorities. Since the rollout of these multi-year strategic initiatives in our fiscal 2019, we’ve been very focused on execution, making impact and delivering results.

While the pandemic continues to present unknowns, what is certain is that fiscal 2023 will be another year in which we focus on strong execution on strategic advancement. Our continued progress towards these four priorities will be a key driver to our sustainable profit growth, strong cash flow, and shareholder value creation. We continue to focus on the things that matter most to our customers, to our patients, to our employees, and to our shareholders.

In closing, we continue to be excited about our future growth prospects as we meet the opportunity as a diversified healthcare services company. We have unique and differentiated assets in oncology and biopharma services with unmatched scale and connectivity. And we’re strategically positioned to win in these growing markets.

And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of a 76,000 employees that make up team McKesson. We share a mission to improve healthcare in every setting. And that will be achieved only with the dedication and the commitment from our people. And for the opportunity to work alongside this amazing team. I continue to be humbled and deeply grateful.

Thank you for your time this afternoon. Britt, I’ll pass it to you.

Britt Vitalone

Thank you, Brian. And good afternoon, everyone. I’m pleased to be here today to discuss our fiscal third quarter results, which reflects another quarter of strong performance across the business driven by operational execution against our growth strategies.

In the third quarter, we delivered overall growth compared to the prior year results across each of our segments including growth over the prior year on excluding COVID-19 related programs. Let me start with an update on Europe. We remain committed to fully exit the European region and the progress of our exit activities are on track.

Today we announced the transactions to sell our Austrian business to Quadrifolia Management and the sale of McKesson remaining share of our German joint ventures to Walgreens Boots Alliance closed on January 31 of ’22. The assets involved in the Austrian transaction contributed approximately $1.5 billion in revenues and $50 million in adjusted operating profit in fiscal 2021. The earnings related to our German joint venture were immaterial.

Next pursued to the satisfaction of customary closing conditions, including receipt of regulatory approvals. We anticipate the pending divestiture to sell McKesson’s U.K. retail and distribution businesses will close in the fourth quarter of fiscal 2022. And the transaction to sell certain European assets to the PHOENIX Group will close in the first half of fiscal 2023.

The net assets included in these transactions are classified as held for sale. Our fiscal 2022 guidance includes approximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which is recorded within our international segment. This $0.49 of accretion resulting from the held for sale accounting will conclude once each transaction is closed.

For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share of accretion related to the held for sale accounting based on the current estimated close date for the PHOENIX Group transaction. Norway and Denmark remain the only countries that we have not entered into an agreement to sell.

As previously discussed, we anticipate we’ll deploy capital to offset dilution resulting from all European divestitures principally through share repurchases. Before I provide more details on our third quarter adjusted results, I want to point out one additional item that impacted our GAAP only results in the quarter.

We recorded a gap only after-tax charge of $829 million related to the sale of retail and distribution businesses in the U.K. to account for the remeasurement of the net assets to the lower carrying amount or fair value, less cost to sell. These charges were largely driven by declines in the British pound sterling.

Moving now to our adjusted results for the third quarter. Beginning with our consolidated results which can be found on Slide 7. As discussed in our Investor Day event in December, we manage the business for the long-term and our financial and strategic framework is focused on shareholder value creation. Our financial framework combined three key elements to generate sustainable adjusted EPS growth, organic growth, operating leverage and capital allocation. This framework is once again demonstrated by our strong third quarter fiscal 2022 results.

Additionally, our leadership supporting the U.S. governments COVID-19 domestic and international vaccine and kitting efforts continues to contribute to growth and the momentum we have built across the business. Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year. This result was driven by strong operational performance across the segments. COVID-19 related items, which include the contribution from COVID-19 vaccine distribution, kitting and storage programs of the U.S. government. COVID-19 tests in fiscal 2021 impairments of personal protective equipment and related products, and a lower share count.

Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the U.S. Pharmaceutical segment largely due to higher volumes from our retail national account customers. And branded pharmaceutical price increases, which were in line with our initial guidance, partially offset by branded to generic conversions. Adjusted gross profit was $3.4 billion for the quarter and increase of 8% compared to the prior year, which benefited from the increased contribution from our strong operational performance and previously mentioned COVID-19 programs and related items.

Adjusted operating expenses in the quarter increased 1% year-over-year, excluding the impact of held for sale accounting and announced divestitures in the international segment adjusted operating expenses increased 2% year-over-year. Adjusted operating profit was $1.3 billion for the quarter an increase of 19% compared to the prior year led by strong operational performance across the segments.

Moving below the line, interest expense was $41 million in the quarter and improvement of 25% compared to the prior year. Our adjusted tax rate was 19.6% for the quarter. And wrapping up our consolidated results, third quarter diluted weighted average shares were $153.5 million, a decrease of 5% year-over-year.

Moving now to our third quarter segment results, which can be found on Slides 8 through 13. Starting with U.S. Pharmaceutical. Revenues were $55 billion, an increase of 11% year-over-year, driven by higher volumes from our retail national account customers and branded pharmaceutical price increases partially offset by branded to generic conversions. Adjusted operating profit increased 12% to $735 million driven by the contribution from COVID-19 vaccine distribution and growth in the distribution of specialty products to hospitals and community conditions.

The contribution from our contract with the U.S. government, with the distribution of COVID-19 vaccines provided a benefit of approximately $0.26 per share in the quarter, which was in line with our expectations. In the prescription technology solution segment, revenues were $1 billion an increase of 33% higher volume growth related to biopharma services, including third-party logistics services and increased technology service revenue, partially resulting from the growth of prescription volumes. Adjusted operating profit increased a 11% to a $145 million driven by growth from access inherent solutions.

We continue to experience growth across our broad spectrum, higher margin capabilities and offerings in this segment. We’re pleased with the increased transaction volumes related to our access inherent solutions, and the increasing number of brands that joined our platforms this year. We also experienced increased volumes in our logistics and hub services, due to the continued recovery of prescription volumes.

Moving now to Medical-Surgical Solutions. Revenues were $3.1 billion, an increase of 1% driven by growth in the primary care business, and the contribution from kitting, storage and distribution of ancillary supplies for COVID-19 vaccines, partially offset by lower revenue from COVID-19 tests in our primary care and extended care businesses as compared to the prior year.

Adjusted operating profit increased 18% to $330 million driven by the contribution from kitting, storage and distribution of ancillary supplies for the U.S. governments COVID-19 vaccine program, the prior year impact of an inventory of impairment charge related to PPE that incurred in the third quarter of fiscal 2021 and growth in the primary care business. The contribution from our contract with U.S. government related to the kitting, distribution and storage of ancillary supplies for COVID-19 vaccines provided a benefit of approximately $0.31 per share in the quarter, which was above our original expectations.

Next, let me address our international results. Revenues in the quarter were $9.5 billion, an increase of 2% driven by new customer growth in our Canadian business, and volume increases in the pharmaceutical distribution and retail businesses across the segment, which were partially offset by the contribution of McKesson’s German wholesale business through joint venture with Walgreens Boots Alliance.

On an FX adjusted basis, adjusted operating profit increased 41% to $223 million, driven by the reduction as compared to the prior year of depreciation and amortization. Uncertain European assets classified as held for sale, the distribution of COVID-19 vaccines and tests in Europe and strong distribution results in our Canadian business. The held for sale accounting in the international segment contributed $0.18 to adjusted earnings in the quarter.

Moving on to corporate, adjusted corporate expenses were $159 million, an increase of 1% year-over-year. We incurred opioid related litigation expenses of $33 million for the third quarter. We anticipate that fiscal 2022 opioid related litigation expenses will be approximately $135 million.

Let me now turn to our cash position, which can be found on Slide 14. We ended the quarter with a cash balance of $2.8 billion. For the first nine months of the fiscal year we generated free cash flow of $1.2 billion. Here to-date it made $380 million of capital expenditures, which included investments to support our strategic pillars of oncology and biopharma services.

For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 billion of share repurchases and the payment of $206 million in dividends. At our Investor Day event in December, we announced that our Board of Directors approved an increase of $4 billion to our existing share repurchase program. At the end of our third quarter $4.8 billion remains on our share repurchase authorization.

With this increased authorization, the completed sales of the Austrian business and remaining share in the German joint venture and the anticipated fiscal fourth quarter closure the sale of the U.K. business, we anticipate executing share repurchases of up to $1.5 billion in the fourth quarter. As a result, we now anticipate returning approximately $3.5 billion to shareholders through share repurchases in fiscal 2022. Our strong operating performance combined with our return of capital to shareholders, reinforces our commitment to driving the shareholder value.

Let me transition and speak to our outlook for the remainder of fiscal 2022. A full list of our fiscal 2022 assumptions can be found in Slide 16 through 18. We continue to anticipate a full recovery of prescription volumes. However, the persistence of COVID-19 and its variants such as Omicron, is leading to a non-linear trajectory. In the U.S. Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to deliver 8% to 10% growth over the prior year. We continue to see stable fundamentals in our U.S. Pharmaceutical business. Specifically, our outlook for branded pharmaceutical pricing of mid single digits increases in fiscal 2022 remains consistent with both our original guidance and prior-year. In our view of the generics environment remains competitive yet stable.

Our guidance remains aligned to the volume distribution schedule provided by the CDC and U.S. government, and includes the contribution related to our role as a centralized distributor for the U.S. government’s COVID-19 vaccine distribution program. We will continue to update you in the progress and contribution from this program.

When excluding COVID-19 vaccine distribution in the segment, we anticipate approximately 3% to 6% adjusted operating profit growth. And as a reminder, our investments in our leading and differentiated position in oncology will continue to represent an approximate $0.20 headwind in fiscal 2022.

In our Prescription Technology Solutions segment, we anticipate revenue growth of 32% to 36%, and adjusted operating profit growth of 24% to 28%. This growth reflects the strong momentum in the business, as we project increased volumes across new and existing biopharma solutions and customers.

Transitioning to medical surgical, our outlook assumes 15% to 19% revenue growth, and adjusted operating profit growth of 51% to 55% over the prior-year. Our outlook includes $0.85 to $1.05 related to the contribution from the U.S. government’s distribution of ancillary supply kits, and storage programs and $0.75 to $0.95 related to the net impact of COVID-19 tests, and PPE impairments and related products.

When excluding the impacts of these items in the segment, we anticipate 22% to 26% growth over the prior-year. One additional reminder related to our U.S. distribution businesses. On our earnings call in November, we discussed the highly competitive labor market, which continues to persist. We also outlined an assumption for modest labor related expense impact to ensure support of our talent strategy and continued service continuity through the second half of our fiscal year.

Based on labor market trends experienced in the third quarter and our expectations for the remainder of the fiscal year, we continue to anticipate approximately $0.10 to $0.20 of adjusted operating expense impact in our U.S. distribution businesses in the second half of the year, weighted slightly higher in our Medical segment.

Finally, in the International segment, our revenue guidance 2% decline to 1% growth as compared to the prior-year. And as a reminder, this reflects the impact from the contribution of our German wholesale business to a joint venture with Walgreens Boots Alliance in the third quarter of fiscal 2021.

For adjusted operating profit, our guidance reflects growth in the segment of 43% to 47%. This includes approximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held for sale accounting related to our agreement to sell certain European assets.

Turning now to the consolidated view. Our increased guidance assumes 8% to 11% revenue growth and 24% to 27% adjusted operating profit growth compared to fiscal 2021. Our full-year adjustment effective tax rate guidance of 18% to 19% remains unchanged and we anticipate corporate expenses in the range of $570 million to $620 million an improvement from the previous range of $610 million to $660 million related to our focus on operating leverage, which we highlighted at our recent Investor Day event.

Let me now turn to cash flow and capital deployment. We expect our businesses to continue to drive strong free cash flows and returns on capital even as we continue reinvesting to support sustainable long-term growth. This strong free cash flow generation provides financial flexibility to execute a balanced capital allocation approach including investing in our strategic growth pillars of oncology and biopharma services, while remaining committed to returning capital to shareholders through our growing dividends and share repurchases.

Our investment grade credit rating remains a priority and it underpins our financial flexibility. For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of property acquisitions and capitalized software expenses. As a reminder, historically, we generate a larger portion of our cash flows in the fourth quarter of our fiscal year. Our working capital metrics and resulting cash flows vary from quarter-to-quarter, impacted by timing, which could include the timing of planned European divestiture activity.

We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal 2022. This includes the impact of the anticipated 1.5 billion of fourth quarter share repurchases mentioned earlier.

As a result of our strong year-to-date performance and our outlook for the remainder of the fiscal year, we are raising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, which is above our previous range of $22.35 to $22.95. Our updated outlook for adjusted earnings per diluted share reflects 37% to 39% growth compared to the prior-year.

Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable to the following items, $0.90 to $1.10, related to the U.S. government’s COVID-19 vaccine distribution, $0.85 to $1.05 related to the kitting storage and distribution of ancillary supplies, $0.75 to $0.95 related to COVID-19 tests in the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range of $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures Equity Investments which are within our corporate segment.

Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to 33% forecast growth over the prior-year. When you pull it all together, our strong performance in our outlook equates to an adjusted earnings per diluted share guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day, the $1.10 adjusted earnings per diluted share increase includes the following. Approximately $0.45 driven by strong underlying business performance and operating leverage, approximately $0.22 related to COVID-19 tests, approximately $0.22 related to held for sale accounting and reduced opioid litigation expenses, and approximately $0.20 related to NCI interest expense and lower weighted average shares outstanding.

Let me spend just a minute providing some initial thoughts on fiscal 2023. I want to point out that we are not providing fiscal 2023 guidance at this time. However, I thought it would be instructive to walk you through some of the items that could impact fiscal 2023 as we sit here today.

First, the COVID 19 pandemic continues to present many unknowns, we continue to expect to full recovery. However, it is likely to continue to be non-linear into fiscal 2023 and it could impact a quarterly cadence. In the U.S. Pharmaceutical and Medical Surgical Solution segments, our contracts with the U.S. government to serve as the centralized distributor of COVID-19 vaccines and to assist with the kitting storage and distribution of ancillary supplies are scheduled to expire in July of 2022.

Outside of the contract with U.S. government for COVID-19 vaccine distribution, we anticipate normal customer renewal activity in the U.S. Pharmaceutical segment. As it relates to COVID-19 tests, we continue to anticipate the demand will be closely associated with a rate of COVID case levels and the impact from this will moderate from prior-year levels.

For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accretion in the first half of fiscal 2023 related to the held for sale accounting based on the current estimated closed date for the Phoenix Group transaction. We will no longer record revenue adjusted operating profit or held for sale accounting benefits related to these transactions once the transactions close.

We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance, until we have a completed assessment of government entity participation in the proposed settlement and a final determination regarding that settlement. We will continue to update you on the outcome of that determination and remaining opioid litigation expenses. We anticipate further investment to support the growth of our two key strategies of oncology and biopharma services.

Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into fiscal 2023 and we remain optimistic about future growth opportunities. We’ll share more details with you about our fiscal 2023 outlook at our fourth quarter earnings call in May. In closing, we are pleased with the results of our fiscal third quarter and we have a strong financial outlook. McKesson continues to deliver strong results as we successfully execute against our strategic and financial framework.

We continue to focus on the things that matter most to our customers, patients and shareholders as a diversified healthcare services company. I want to thank you and thank all of our employees for all their hard work and dedication. Now I’ll turn the call over to the operator for your questions.

Question-and-Answer Session


Thank you. [Operator Instructions] Our first question will come from Eric Percher with Nephron Research.

Eric Percher

Thank you and appreciate the commentary on fiscal year ’23. At this point, one thing I want to zero in on relative to the EU. So you’ll remove most of the factors $0.10 of benefit continuing to flow through. As you speak to offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of and do you expect your – how will you judge that? Will you judge it over the full fiscal year given that the timing is still variable?

Brian Tyler

Thanks, Eric for that question. As I talked about in my remarks, we do anticipate that the Austrian transaction, the German transaction, which have already closed, we anticipate that the U.K. transaction will also close in the fourth quarter. So consistent with our comments, we do intend to offset the dilution. And that is one of the reasons why we intended to do some fourth quarter share repurchases, we will continue to apply the principles of our share repurchase activity and certainly we’ll look at cash that is in excess of what we need to operate the business as well as other opportunities that we have to deploy that capital, whether that be additional share repurchases for our shareholders, or if we have M&A transactions.

So certainly we told you, we would offset the dilution. We’re closing transactions now and anticipate more in the fourth quarter. And so that was one of the reasons why we wanted to begin the share repurchase activity, in addition to being very consistent with our share repurchase principles.

Rachel Rodriguez

Next question, please.


And our next will be from Lisa Gill with JPMorgan.

Lisa Gill

Thanks very much. Good afternoon, and thanks for all the detail. Britt, I just want to go back and talk about inflation. You talked a little bit about labor. And I know you and Brian talked last quarter about some special bonuses and increasing wages. But how do we think about wages going forward as we continue to have wage inflation would be my first part of the inflation question. And then secondly, as we think about product inflation, or transportation, I know generally speaking, it’s a passthrough on the pharmaceutical side of things. But how do we think about any PPE on your medical side of your business?

Britt Vitalone

Lisa, thanks for that question. Maybe I’ll just step back for a minute and just address labor and inflation separately, and maybe I’ll just start with inflation. Our business model has a normal component that’s built into it that relates to pricing, you have a model like we do that’s founded on both supply and service stability and consistency, that solves problems, but in a better way for customers and patients, we are able to incorporate some of these higher input costs, through pricing.

Our organization, as Brian has talked about continues to do really a tremendous job in productivity efforts. And those productivity efforts enable us to offset some of this cost. And then of course, there is a pricing component. Just finally, we have an organization of really smart people that are continuously working to find better solutions, greater efficiencies, in leveraging the scale and broad expertise that we have to provide quality and reliability that our customers have come to expect from McKesson. So that’s maybe just answering some of the questions on the inflation front.

In the labor front, Brian’s talked about talent being one of our key components of our strategy, and will remain that and of course, this is a very challenging market. We’re seeing pressures in the labor market. And so we’ve talked about the fact that we expect some of these labor pressures to find their way into operating expenses in the second half of the year $0.10 to $0.20. We’ve not guided beyond FY ’22, we’ll obviously assess if we think that those costs are going to be sustained in any way at this point, we just see a $0.10 to $0.20 impact in our U.S. distribution businesses in the second half, what we’ve seen so far in the third quarter, it’s tracking right in line with that.

Brian Tyler

We will stay on top of the market, we’ll be responsive to it, we got a lot of confidence in our team’s ability to adjust. And we actually think we’ve got an asset in terms of the company culture, our purpose, our mission, the investments we make in our teams, we think this is a great place to work and we’ll continue to find ways to attract the best talent.

Rachel Rodriguez

Next question, please.


And next will be Charles Rhyee with Cowen. Please go ahead.

Charles Rhyee

Yes, hey, thanks for taking the question. Britt, you talked earlier in your prepared comments about in the Pharma Technology Solutions segment about access to medications. And you highlight a couple of businesses, you mentioned a $15 billion market opportunity here. Maybe if you can just give us a little more details around sort of your position in the market, in this part of the market particularly and what is the competitive landscape? And do you see an opportunity here for McKesson to consolidate in this industry?

Brian Tyler

Thank you for the question. I think you addressed it to Britt, but I’ll jump in and start with my thoughts. I mean, so this we think we’re extremely well positioned in this marketplace. And one of the things when we’re anchoring our growth strategies, we try to anchor around is making sure we have differentiation that we have things that are difficult to replicate. And the reason we brought these businesses together as a segment is because we think individually, they all had their strengths and we’re winning in their market, but collectively together accessing the reach of our networks, utilizing the advanced technologies, we have in CoverMyMeds and then the clinical expertise and the biopharma relationships, we had in RxCrossroads, they kind of reinforce and compound each other.

And so we think about the access as distinct market, adherence is a distinct market, outcomes is a distinct market, but by putting these together, it allows us to really more effectively compete across all of those some of that is reinventing a better solution for a market that exists. That’s sort of what we did with AMP, we brought in infusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us what we think is a significant competitive advantage. We’ll continue to do those kinds of innovations as we grow into it. I mean, it is a pretty fragmented landscape.

There are some competitors names you know, there’s frankly lots of little ones. This is an area that we would like to use the strength of our balance sheet to be acquisitive, to be additive to that ecosystem through additional capability or additional scale. As long as we find that strategically aligned asset and it can meet our financial hurdles and stand up well to other means, we have to deploy capital, we’ll certainly look to execute on that.

Rachel Rodriguez

Next question, please.


And the next one will be from Jailendra Singh with Credit Suisse. Please go ahead.

Jailendra Singh

Thank you, and hello, everyone. So we just go to $0.45 core business outperformance, you called out which is now captured in your fiscal ’22 outlook. How do you think about the sustainability of some of those drivers behind that outperformance and related to that how should we think about the fiscal ’22 baseline EPS of $17.50 to $18 you share that is today?

Brian Tyler

Let me take those in two pieces. We’re pleased with another quarter of strong operating performance and obviously saw growth across each of our segments. So as we look at the outlook for the remainder of the year, we expected the momentum in our business is going to continue. And we haven’t provided any guidance as it relates to FY ’23 but in our Investor Day, we did provide long-term targets where we suggested and felt very confident that we’ll continue to see growth in each of those segments for the long-term. So we feel very good about the performance that we’re seeing in our business and consistent with our Investor Day, we expect that to continue.

So I think that is really the point that you should see just continued strong performance for several years now across all of our segments with the fundamentals of our businesses are strong, we’re investing in these businesses for future growth. And we’re in markets that we think are going to continue to grow and we’re in very good positions to take advantage of that with some differentiated capabilities.

Rachel Rodriguez

Next question, please.


And next will be Michael Cherny with Bank of America.

Michael Cherny

Good afternoon, and thanks for the color so far. I want to talk a little bit about the U.S. pharma segment. As you think about into next year and thinking more qualitatively as much as anything else. But how do you think about outside of the COVID related script and volume recovery, the other moving pieces. You did comment on a normalized renewal year? So are there any things you’re seeing there big renewals, and how you think about the areas of growth that have remain steady, maybe within specialty and the potential for biosimilars? And how that should factor into that long-term growth trajectory and where that falls relative to ’23 broadly?

Britt Vitalone

Mike, thanks for the question. Maybe I’ll start, and then I’ll let Brian jump in here. Again, I – as we think about it, and some of the things that I mentioned here. We do expect a full recovery of prescription transaction volumes. And we’re certainly pleased that transaction volumes have continued to increase throughout the year, it has not been in a straight line. But we do expect that full recovery to continue. We’re very well positioned in the specialty clinic space, as well as on oncology, making investments in those areas that we think are going to continue to pay off over the long-term.

And biosimilars is one of those areas that given our position, particularly in oncology. We believe that it’s going to be a growth driver for us over the long-term. We’re pleased with the development of biosimilars to this point, we think that they offer a better returns than branded and specialty products, not at the same level as generics from a margin perspective. But still, were we believe and were optimistic that they’re going to continue to add value to the segment over time.

So the position that we have, the strength that we have across segments, but particularly our differentiated capabilities in oncology. Your positions is very well for further growth.

Rachel Rodriguez

Next question, please.


And next will be Brian Tanquilut with Jefferies.

Brian Tanquilut

Hey, good afternoon, guys. Congrats to the quarter. I guess Britt my question is the medical segment, operating income rates was pretty significant. Even if you backed out, COVID? Can you just dissect for us that outperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?

Britt Vitalone

Thanks for the question, Brian. Maybe I’ll just start just to remind you, since fiscal ’19, this business has grown at 10% from an adjusted operating profit perspective. On the core basis outside of COVID programs. So we’ve seen strong growth in this business now for a number of years. It’s one of our higher margin segments. We have very strong positions across the primary care segment of the business. And across all alternate sites, your extended care business has grown nicely over time as well.

We’ve added a lot of capabilities and investment over time, whether that be acquisitions to position us well in lab. We’ve seen private brand be an important component. And we’ve seen growth in Rx as well. So we’ve got a lot of capabilities across the entire alternate site. We’ve invested in these capabilities over time. It’s positioned us well, not only from a core perspective, but certainly now as COVID has taken on. We’ve been in really good position to handle the kitting and the storage programs as well.

Rachel Rodriguez

Next question, please.


And next will be Rick, excuse me, Ricky Goldwasser with Morgan Stanley.

Ricky Goldwasser

Yes. Hi, good evening, and thanks for the very comprehensive details. So two follow-ups here. One, just to clarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the dilution from the European divestitures that’s first?

And then secondly, as we think about the COVID impact, when we clearly did nice contribution in the last couple of years. How do you think the economics of vaccine in testing will evolve is sort of COVID becomes more of an annuity is. Should we think about it as is flu type economics?

Britt Vitalone

Ricky, let me take the first one. And then I’ll let Brian come on the second. Just because more mechanical question. As I mentioned in my comments, we do expect to offset any dilution from the European divestitures through capital deployment. And that could be share repurchase activity like we’re doing in the fourth quarter. So just to reaffirm that we will be – we do plan on offsetting that dilution.

Brian Tyler

Ricky relative to I guess it’s called the future of testing. That’s a little bit, I think difficult to forecast. And a lot of it will depend on the science, the development, a lot of it will depend on the current testing hold up to current and future potential variants. What will be the mix between, in a medical setting versus over the counter that those become more reliable. I think there’s a lot of questions that still have to resolve themselves there.

What I would say though is, regardless of how that evolves, we think McKesson is in an excellent position to capitalize on that. We are currently the largest distributor, we distribute more flu vaccine than anyone. We have a great franchise in the physician alternate site setting. We distribute to pharmacies, because of our presence in the communities in both our medical and pharmaceutical business, our relationships with the labs, and I think the real credibility we’ve built up over the last couple of years, I think we’re extremely well positioned to capture that opportunity, however it unfolds.

Rachel Rodriguez

We have time for one more question.


Most certainly. And this question will come from Steve Valiquette with Barclays.

Steven Valiquette

Thanks. Good afternoon. I also have a question just around the – your comment around the normal customer renewal activity in fiscal ’23. I guess I just wanted to make sure and confirm the messaging around that. So I guess first, can you remind us how customer renewal activity and any related pricing step downs trended for fiscal ’22. In those, if that activity is going to be normal in ’23. Is that net positive, net negative or net neutral. As you think about the how all that flows year-over-year? Hopefully that question makes sense. Thanks.

Britt Vitalone

Yes. Thanks, Steve, that’s a good question. I’m happy to answer that. And I’m happy to clarify. When I speak of normal, what I mean by that is in any year, we typically see about a third of our U.S. pharmaceutical book renewal. As we have seen over the last few years, there has been no material impacts to that. And certainly, we’ve been able to renew all of our customers successfully within our guidance.

And I would not anticipate that we would see anything material from our – next year. It’s early, obviously, if there’s an update to that information will provide it on our May earnings call. But normal, what I was referring to is that about a third of our book renews every year would not anticipate anything that would be a material driver from that activity.

Brian Tyler

Great. Well, thanks again, everyone for joining us on this call. And thank you for the insightful and very thoughtful questions. Keith, thank you for help facilitating the call. I wanted to just conclude by reiterating McKesson executed really well in the third quarter with double-digit adjusted operating profit growth in all segments. I continue to be excited about the focus on our company priorities and the contributions we can see that making the strong financial results.

It’s really the driver between – the driver of our shareholder value creation. So none of that happens without the team that makes up McKesson. And so, to everyone, in McKesson, no matter what your role, no matter what geography you work in, whether you’re on the frontline or elsewhere in the business. I’m so appreciate of their hard work, their dedication to our purpose and our mission. Their commitment to our customers. They really are what makes this a special place. So thanks to them. Again thank you everyone, I hope you have a terrific evening. Be safe and stay healthy.


Thank you for joining today’s conference call. You may now disconnect and have a great day.

Source link